Berger Financial Group Inc Takes Position in iShares Biotechnology ETF (NASDAQ:IBB)

Berger Financial Group Inc purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,591 shares of the financial services provider’s stock, valued at approximately $343,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Ally Invest Advisors Inc. increased its stake in shares of iShares Biotechnology ETF by 5.3% in the 4th quarter. Ally Invest Advisors Inc. now owns 1,515 shares of the financial services provider’s stock worth $200,000 after purchasing an additional 76 shares in the last quarter. Arete Wealth Advisors LLC increased its stake in shares of iShares Biotechnology ETF by 4.2% in the 4th quarter. Arete Wealth Advisors LLC now owns 1,990 shares of the financial services provider’s stock worth $263,000 after purchasing an additional 80 shares in the last quarter. TD Private Client Wealth LLC increased its stake in iShares Biotechnology ETF by 3.0% in the 4th quarter. TD Private Client Wealth LLC now owns 2,746 shares of the financial services provider’s stock worth $363,000 after buying an additional 81 shares in the last quarter. Cullen Frost Bankers Inc. increased its stake in iShares Biotechnology ETF by 1.5% in the 4th quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock worth $748,000 after buying an additional 82 shares in the last quarter. Finally, Transcend Capital Advisors LLC increased its stake in iShares Biotechnology ETF by 0.8% in the 4th quarter. Transcend Capital Advisors LLC now owns 10,958 shares of the financial services provider’s stock worth $1,449,000 after buying an additional 92 shares in the last quarter. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of IBB stock opened at $124.62 on Tuesday. iShares Biotechnology ETF has a 52-week low of $107.43 and a 52-week high of $150.57. The firm has a market capitalization of $5.50 billion, a PE ratio of 25.09 and a beta of 0.84. The stock has a fifty day simple moving average of $128.01 and a two-hundred day simple moving average of $134.81.

iShares Biotechnology ETF Increases Dividend

The firm also recently declared a dividend, which was paid on Friday, March 21st. Shareholders of record on Tuesday, March 18th were paid a $0.1212 dividend. The ex-dividend date of this dividend was Tuesday, March 18th. This is a positive change from iShares Biotechnology ETF’s previous dividend of $0.06.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.